全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Rabies Post-Exposure Prophylaxis in the Philippines: Health Status of Patients Having Received Purified Equine F(ab')2 Fragment Rabies Immunoglobulin (Favirab)

DOI: 10.1371/journal.pntd.0000243

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Recommended treatment for severe rabies exposure in unvaccinated individuals includes wound cleaning, administration of rabies immunoglobulins (RIG), and rabies vaccination. We conducted a survey of rabies treatment outcomes in the Philippines. Methods This was a case series involving 7,660 patients (4 months to 98 years of age) given purified equine RIG (pERIG) at the Research Institute for Tropical Medicine (Muntinlupa, Philippines) from July 2003 to August 2004 following Category II or III exposures. Data on local and systemic adverse reactions (AR) within 28 days and biting animal status were recorded; outcome data were obtained by telephone or home visit 6–29 months post-exposure. Results Follow-up data were collected for 6,464 patients. Of 151 patients with laboratory-confirmed rabies exposure, 143 were in good health 6–48 months later, seven could not be contacted, and one 4-year-old girl died. Of 16 deaths in total, 14 were unrelated to rabies exposure or treatment. Two deaths were considered PEP failures: the 4-year old girl, who had multiple deep lacerated wounds from a rabid dog of the nape, neck, and shoulders requiring suturing on the day of exposure, and an 8-year-old boy who only received rabies PEP on the day of exposure. Conclusions This extensive review of outcomes in persons with Category III exposure shows the recommended treatment schedule at RITM using pERIG is well tolerated, while survival of 143 laboratory-confirmed rabies exposures confirms the intervention efficacy. Two PEP intervention failures demonstrate that sustained education and training is essential in rabies management.

References

[1]  Rupprecht CE (2004) A tale of two worlds: public health management decisions in human rabies prevention (editorial commentary). Clin Infect Dis 39: 281–283. doi: 10.1086/421563
[2]  Anonymous (2005) WHO Expert Consultation on Rabies: First Report. Technical Report Series 931. Geneva: WHO. (Also available at http://www.who.int/rabies).
[3]  Servat A, Lutsch C, Delore V, Lang J, Veitch K, Cliquet F (2003) Efficacy of rabies immunoglobulins in an experimental post-exposure prohylaxis rodent model. Vaccine 23: 244–249. doi: 10.1016/S0264-410X(03)00559-0
[4]  Lang J, Attanah P, Quiambao B, et al. (1998) Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Tropica 70: 317–333. doi: 10.1016/S0001-706X(98)00038-2
[5]  Robles CG, Miranda NLJ (1992) Comparative evaluation of the rabies fluorescent antibody test and direct microscopic examination at the Research Institute for Tropical Medicine. Phil J Microbiol Infect Dis 21: 69–72.
[6]  Anonymous (1996) Recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. No21WHO/EMS/ZOO 96.6 Geneva: WHO; 1996.
[7]  Ali NS (2003) Guidelines for prophylaxis of rabies in Pakistan. Pak J Med Sci 219: 61–65.
[8]  Chantanakajornfung A, Narapron N, Khumphai W, Bejavongkulchai M, Mitmoonpitak C, Wilde H (1999) A study of human rabies immune globulin manufactured by the Thai Red Cross. Vaccine 17: 979–981. doi: 10.1016/S0264-410X(98)00314-4
[9]  Sudarshan MK, Madhusudana SN, Mahendra BJ, et al. (2007) Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 11: 29–35. doi: 10.1016/j.ijid.2005.10.007
[10]  Suwansrinon K, Jaijaroensup W, Wilde HY, Sitprija V (2006) Short Report: is injecting a finger with rabies immunoglobulin dangerous? Am J Trop Med Hyg 75: 363–364.
[11]  Hanlon CA, Niezgoda M, Morrill PA, Rupprecht CE (2001) The incurable wound revisited: progress in human rabies prevention? Vaccine 19: 2273–2279. doi: 10.1016/S0264-410X(00)00516-8
[12]  Quiambao BP, Laot T, Castillo Y, Teuwen DE, Zinsou J-A (2005) Rabies post-exposure prophylaxis (PEP) policy at RITM, Manila, Philippines (abstract) XVIth International Conference on Rabies in the Americas, Ottawa, Canada.
[13]  Sampath G, Parikh S, Sangram P, Briggs DJ (2005) Rabies post-exposure prophylaxis in malnourished children exposed to suspect rabid animals. Vaccine 23: 1102–1105. doi: 10.1016/j.vaccine.2004.08.036

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133